Navigation Links
Jefferson researchers uncover new evidence of prolactin's possible role in breast cancer
Date:9/28/2007

(PHILADELPHIA) Scientists at the Kimmel Cancer Center at Jefferson in Philadelphia have discovered new molecular evidence of the role of the hormone prolactin in breast cancer. They have found that prolactin, a pituitary hormone that normally stimulates breast development and milk production, initiates a new signaling pathway that may regulate the growth and survival of breast cancer cells.

The work, which appears this month in the journal Molecular Endocrinology, identifies the protein Jak1 as playing a key part in prolactin signaling in breast cancer. Jak1, which belongs to the cell growth-promoting tyrosine kinase class of enzymes, could represent a new drug target for treating breast cancer.

In breast cancer cells, we found that Jak1 not only stimulates conventional prolactin signaling via proteins such as Stat5, but also that Jak1 recruited new signals, especially Stat3 and ERK, says Hallgeir Rui, M.D., Ph.D., professor of Cancer Biology at Jefferson Medical College of Thomas Jefferson University and principal investigator of the study. Because Stat3 and ERK typically are considered tumor-promoting, inhibitors of Jak1 may become useful in breast cancer treatment.

Receptors for prolactin, have previously been shown to promote breast cancer cell growth, survival, and differentiation, Dr. Rui explains, through signaling pathways that involve activation of such proteins as Stat5, ERK, and Akt. Prolactin is also known toactivate Stat3, which has been implicated as an oncogene involved in cancer cell growth and survival. In the current study, when Jak1 protein expression was experimentally disrupted in breast cancer cells, prolactin signaling through Stat3 and ERK was completely blocked. Signaling through Stat5 and Akt was reduced but still present.

Until now, prolactin was believed to signal only through Jak2 to mediate its effects, says Lynn Neilson, Ph.D., a postdoctoral fellow in the Department of Cancer Biology at Jefferson Medical College and first author of the study. The unexpected finding that prolactin also activates Jak1 in breast cancer points to a mechanism in cancer cells that further promotes tumor cell growth.

Dr. Ruis laboratory currently is seeking to determine the role of Jak1 in breast cancer cell growth, survival, and invasion, which will be important for establishing the potential usefulness of Jak1 as a new drug target in patients. Prolactin is secreted by the pituitary gland, and important for milk production during lactation. Receptors for this hormone are present on a majority of breast cancers. Prolactin levels in blood are relatively unaffected by menopause, and breast cancer patients are exposed to the hormone across all age groups.


'/>"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Jefferson Physicians Report on Potentially Fatal Complication of Heart Attack
2. Jefferson Researchers Want to Learn If Heart Defect at Heart of Some Migraines
3. Researchers urge caution in using ear tube surgery
4. Researchers Scale to assess the Severity of Epilepsy in Kids
5. Researchers identify the early makers of Neonatal Sepsis
6. OHSU Researchers Announce New Discovery
7. Researchers Identify Gene Connected To Bipolar Disorder
8. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
9. Researchers trick Alzheimers Enzyme
10. Researchers find new HIV hiding place
11. Gene researchers make Malaria-resistant mosquito
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Cut Pro X users can now reveal the media of their split screens ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Australia,s successful biotechnology scientists, Dr Graham ... Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is seeking ... ASX. Noxopharm is a clinic-ready company with its first ... study later this year. NOX66 ... cancer patients - the ability of cancers to become resistant to ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: